Tissue-resident FOLR2 + macrophages associate with CD8 + T cell infiltration in human breast cancer.

Autor:	Nalio Ramos R; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France., Missolo-Koussou Y; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France., Gerber-Ferder Y; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France., Bromley CP; Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, UK., Bugatti M; Department of Pathology, University of Brescia, Brescia 25123, Italy., Núñez NG; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France., Tosello Boari J; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France., Richer W; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France., Menger L; PSL University, Institut Curie Research Center, INSERM U932, 75005 Paris, France., Denizeau J; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France., Sedlik C; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France., Caudana P; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France., Kotsias F; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France., Niborski LL; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France., Viel S; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France., Bohec M; PSL University, Institut Curie Research Center, Institut Curie Genomics of Excellence Platform, 75005 Paris, France., Lameiras S; PSL University, Institut Curie Research Center, Institut Curie Genomics of Excellence Platform, 75005 Paris, France., Baulande S; PSL University, Institut Curie Research Center, Institut Curie Genomics of Excellence Platform, 75005 Paris, France., Lesage L; PSL University, Institut Curie Hospital, Department of Pathology, 75005 Paris, France., Nicolas A; PSL University, Institut Curie Hospital, Department of Pathology, 75005 Paris, France., Meseure D; PSL University, Institut Curie Hospital, Department of Pathology, 75005 Paris, France., Vincent-Salomon A; PSL University, Institut Curie Hospital, Department of Pathology, 75005 Paris, France., Reyal F; PSL University, Institut Curie Hospital, Department of Surgery, 75005 Paris, France., Dutertre CA; Université Paris-Saclay, Institut Gustave Roussy, INSERM U1015, Villejuif, France., Ginhoux F; Université Paris-Saclay, Institut Gustave Roussy, INSERM U1015, Villejuif, France; Singapore Immunology Network, Agency for Science, Technology and Research, Singapore 138648, Singapore., Vimeux L; University of Paris, Institut Cochin, INSERM U1016, CNRS UMR 8104, 75014 Paris, France., Donnadieu E; University of Paris, Institut Cochin, INSERM U1016, CNRS UMR 8104, 75014 Paris, France., Buttard B; INSERM, Sorbonne Université, Université de Paris, Centre de Recherche des Cordeliers, Laboratory of Integrative Cancer Immunology, Paris, France., Galon J; INSERM, Sorbonne Université, Université de Paris, Centre de Recherche des Cordeliers, Laboratory of Integrative Cancer Immunology, Paris, France., Zelenay S; Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, UK., Vermi W; PSL University, Institut Curie Research Center, INSERM U932, 75005 Paris, France; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA., Guermonprez P; Université de Paris, Centre for Inflammation Research, CNRS ERL8252, INSERM1149, Paris, France., Piaggio E; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France., Helft J; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France. Electronic address: julie.helft@inserm.fr.
Jazyk:	angličtina
Zdroj:	Cell [Cell] 2022 Mar 31; Vol. 185 (7), pp. 1189-1207.e25. Date of Electronic Publication: 2022 Mar 23.
DOI:	10.1016/j.cell.2022.02.021
Abstrakt:	Macrophage infiltration is a hallmark of solid cancers, and overall macrophage infiltration correlates with lower patient survival and resistance to therapy. Tumor-associated macrophages, however, are phenotypically and functionally heterogeneous. Specific subsets of tumor-associated macrophage might be endowed with distinct roles on cancer progression and antitumor immunity. Here, we identify a discrete population of FOLR2 + tissue-resident macrophages in healthy mammary gland and breast cancer primary tumors. FOLR2 + macrophages localize in perivascular areas in the tumor stroma, where they interact with CD8 + T cells. FOLR2 + macrophages efficiently prime effector CD8 + T cells ex vivo. The density of FOLR2 + macrophages in tumors positively correlates with better patient survival. This study highlights specific roles for tumor-associated macrophage subsets and paves the way for subset-targeted therapeutic interventions in macrophages-based cancer therapies. Competing Interests: Declaration of interests The authors J.H., R.N.R., E.P., and P.G. and their institutions have filed a patent related to this work. (Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu